Oculis enters merger deal with European Biotech Acquisition
Pharmaceutical Technology
OCTOBER 18, 2022
Oculis has signed a definitive business combination agreement with special purpose acquisition company (SPAC) European Biotech Acquisition (EBAC). OCS-02 is a topical anti-TNF alpha monoclonal antibody fragment, while OCS-05 is an activator of serum-glucocorticoid kinase 2.
Let's personalize your content